About Us M&S Decisions provides model-based solutions to support development of new drugs for pharmaceutical companies READ MORE Services M&S Decisions services include population PKPD and quantitative systems pharmacology READ MORE Research M&S Decisions does research in systems biology, immunology, clinical pharmacology, cell dynamics READ MORE News See the info on the latest conferences, collaborations and activities! READ MORE

Optimize your Research and Development with M&S Decisions

Our mission is to develop Drug-Disease modeling platforms to be used as quantitative tools, in support of decision-making across R&D continuum. It’s important to apply such platforms of quantitative knowledge integration towards real projects. Thus it allows to address recurring questions on compound selection, dose & dose scheduling, therapeutic window, biomarker selection, patient populations and selection, combination therapies and study design optimization.

Kirill Peskov, CEO / Кирилл Песков, Генеральный директор ООО «Эм энд Эс десижанс»

Kirill Peskov,
Chief Executive Officer

About M&S Decisions

M&S Decisions is a scientific consulting company, founded in May 2015. We use modeling and simulation techniques to support decision making in drug development.

We have expertise in translational science, quantitative systems pharmacology, population modeling, biostatistics and post-marketing research.

We provide and share our experience across the Skolkovo Biomedical cluster building the strong partnership with scientific startups and society.

in M&S Decisions team
scientific articles
given at conferences

Our Team

Our team has been working together for more than 10 years and consists of 20 associates, including 18 modeling scientists with core expertise in biology, chemistry, systems pharmacology, pharmacokinetics-pharmacodynamics, pharmacometrics, meta-analyses, data mining & machine learning.

Our Expertise



  • Pharmacometrics/PKPD
  • Quantitative Systems Pharmacology/PBPK
  • Biostatistics and Data Sciences
  • Model-Based Meta-Analyses
  • Data Mining & Machine Learning
  • Health Economics & Real-World Evidence Analyses

Disease Areas

  • Oncology including Immuno-Oncology
  • Cardiovascular & Metabolic Diseases
  • Respiratory Diseases
  • Neuroscience and Neurological Diseases
  • Auto-Immune Diseases
  • Ophthalmics
Domains: Fundamental Sciences & Disease Areas, Therapeutic Modalities

Therapeutic Modalities

  • Small molecules
  • Engineered proteins: antibodies, bi/tri-specifics, antibody-drug conjugates
  • RNA-based modalities including antisense nucleotides and siRNA’s
  • Gene- & cell-based therapies

Operations & Tools

  • Software development and integrative tools for modeling workflows: from data collection to report generation
  • Quality & Validation tools including for analyses submitted to Health Authorities worldwide
  • Human resources & associates’ development operations
Operations & Tools

Our Partners


Get more information on our scientific engagement!

We are actively building engagement and impact with the federal and local health authorities through a scientific dialogue and based on quantitative pharmacometrics.